Compare GRNQ & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRNQ | ONCO |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.5M | 2.3M |
| IPO Year | 2014 | 2021 |
| Metric | GRNQ | ONCO |
|---|---|---|
| Price | $2.28 | $0.62 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 18.2K | ★ 341.3K |
| Earning Date | 04-08-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.80 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,673,997.00 | $815,371.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 24.55 | N/A |
| 52 Week Low | $0.84 | $0.05 |
| 52 Week High | $2.50 | $7.65 |
| Indicator | GRNQ | ONCO |
|---|---|---|
| Relative Strength Index (RSI) | 69.37 | 35.74 |
| Support Level | $1.57 | $0.45 |
| Resistance Level | $2.50 | $0.95 |
| Average True Range (ATR) | 0.13 | 0.09 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 94.29 | 11.84 |
Greenpro Capital Corp operates and provides business solution services to small and medium-sized businesses located in Southeast Asia and East Asia, with a focus on Hong Kong, China and Malaysia, and in Thailand and Taiwan. Its range of services includes cross-border business solutions, record management services, and accounting outsourcing services. Cross-border business services include other services, tax planning, trust and wealth management. Its segments include Service business engaged in the provision of corporate advisory and business solution services; Real estate business segment engaged in trading or leasing of commercial real estate properties in Hong Kong and Malaysia; and Digital business segment engaged in provision of digital platform and trading of digital assets.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.